Drug Discovery & Development

Home » Drug Discovery & Development

Enamine and BioSolveIT Launch the World’s Largest Searchable Chemical Space for Novel Compound Sourcing

Enamine Ltd, a leading chemical research organisation and producer of the world’s largest collections of novel building blocks (150,000) and screening compound libraries (2,400,000), and BioSolveIT GmbH, premium provider of medicinal chemistry software, have announced the launch of the REAL Space Navigator. Jointly developed, the new software tool capitalises on Enamine’s REAL (readily accessible) virtual [...]

Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement

Helsinn International Services, a Monaco-based affiliate of the Swiss Pharmaceutical Group focused on building quality cancer care products, and the Scientific Centre of Monaco (CSM), have signed a collaboration agreement to support a research project aimed at developing pharmacological inhibitors for the most common form of kidney cancer: clear cell renal cell carcinoma (ccRCC). ccRCC [...]

Follicum Identifies Receptors in Insulin-Producing Cells for Potential New Class of Diabetes Drugs

Follicum AB has successfully mapped the receptors in insulin-producing cells that bind the company’s peptides. The new knowledge represents an important milestone in the continued development of the company's diabetes project and opens the possibility of the identified receptors becoming potential drug targets for stimulating insulin secretion and reduction of diabetic complications. Investigation of mechanism [...]

Avacta and Oncosec to Collaborate on Innovative Gene Delivery of Therapeutic Affimers

Avacta Group, the developer of Affimer biotherapeutics and reagents, and OncoSec Medical Incorporated (OncoSec), a company developing intratumoral cancer immunotherapies, are pleased to announce they have entered into a research collaboration to combine Avacta’s Affimer protein platform with OncoSec’s gene delivery technology ImmunoPulse. The research programme will evaluate the benefits of delivering Affimer protein genes [...]

Cambrex and AstraZeneca Hold Ceremony to Mark Long-Term Supply Agreement

Cambrex Corporation, the leading manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), recently held an opening ceremony with AstraZeneca, at its Karlskoga, Sweden, site to mark the commencement of a long-term manufacturing agreement between the two companies for a key intermediate. The announcement follows the completion, in 2017, of both a large-scale, [...]

Cancer Research UK and The Institute of Cancer Research Join Forces with Merck in New Drug Discovery Alliance 

Cancer Research UK’s Commercial Partnerships Team and The Institute of Cancer Research, London, announced a multiproject collaboration and licensing deal with Merck, a leading science and technology company, to discover and develop new anticancer drugs, today (Wednesday). This multiproject deal follows previous single project drug discovery collaborations and a more recent target validation collaboration between Merck and [...]

CombiGene and Cell and Gene Therapy Catapult to Develop Manufacturing Process for Novel Gene Therapy to Treat Epilepsy

CGT Catapult and CombiGene have announced that they will be collaborating on a project to develop manufacturing processes for CombiGenes drug candidate CG01, a novel gene therapy for treatment of epilepsy. The collaboration aims to develop a complete and final manufacturing process that will allow CombiGene to progress to commercial GMP production and thereafter clinical [...]

Styrian Scientists Help to Improve Access to Critical Medicines

Today, one third of the world’s population lacks access to essential medicines. The Research Center Pharmaceutical Engineering (RCPE) — as part of the Medicines for All Institute (M4ALL) in the US — aims to improve access to lifesaving medicines by developing more cost-effective and efficient technologies to synthesise the active ingredients. Last summer, Virginia Commonwealth [...]

Cypralis to Hold Exclusive Development and Commercialisation Rights to Cyprolides for acute and Chronic Degenerative Diseases

Cypralis and Gilead Sciences, Inc. have agreed that Cypralis will have exclusive development and commercialisation rights to certain macrocyclic inhibitors of peptide bond isomerases, in all fields except for oncology and virology. This is a further step in the collaboration between the parties which follows a multi-year drug discovery collaboration between Selcia Ltd (Ongar, Essex) and Gilead (Foster [...]

DelMar Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma

DelMar Pharmaceuticals, Inc. a biopharmaceutical company focused on the development and commercialisation of new cancer therapies, has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the company's lead product candidate, VAL-083, in recurrent glioblastoma (rGBM). "The Fast Track designation marks an important milestone in the development of VAL-083 as [...]